Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials
Since its Reg A+ launch, InSitu Biologics has sold-out of three SEC qualified price tiers. InSitu has since paused its Offering and will be submitting a new valuation and price qualification to the SEC to better reflect milestone achievements and business developments.
In pre-clinical studies, AnestaGel has proven to be a fast acting and long lasting, non-opiate painkiller, targeted for use in post-operative regional pain management and is expected to be explored for use in numerous surgical applications. Prior to the Reg A+ funding, InSitu Biologics published a peer-reviewed preclinical study in the Journal of Pain Research which found that AnestaGel:
- Consistently lasted up to 300% longer when compared to the leading liposome-based sustained-release drug;
- Had full nerve block beyond 72 hours (24-48 hours for liposome-based drug) and;
- Carried 8x more painkiller than liposome-based drugs, remaining non-toxic.
“Development of non-addictive, non-opioid pain drugs lag far behind research for other diseases,” said James Segermark, President and CEO. “Addiction often begins with post-operative pain management, for which there are few non-opiate solutions. Our investors understand that a change is required.”
The Securities and Exchange Commission (SEC) Qualified InSitu on July 17, 2018, to raise up to $10 million using Reg A+. Reg A+ allows private companies to raise up to $50 million from the general public over a 12 month period. The SEC qualified Form 1-A can be found here: https://www.sec.gov/Archives/edgar/data/1723443/000147793218002887/insitu_1a.htm
The Company is audited by the CPA firm of Baker Tilly Virchow Krause. The Offering Circular, and ability to make an investment reservation can be found athttps://www.manhattanstreetcapital.com/insitu-biologics-0